{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T17:09:49Z","timestamp":1788714589671,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,6]]},"DOI":"10.7759\/cureus.115859","type":"journal-article","created":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T16:50:08Z","timestamp":1788713408000},"source":"Crossref","is-referenced-by-count":0,"title":["Triple M Overlap Syndrome: A Rare Complication of Immune Checkpoint Inhibitors"],"prefix":"10.7759","author":[{"given":"Brian","family":"Morris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider BJ","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021, 39:4073-126. 10.1200\/JCO.21.01440","journal-title":"J Clin Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(23)00524-7","article-title":"Treatment-related adverse events, including fatal toxicities, in patients with solid tumours receiving neoadjuvant and adjuvant immune checkpoint blockade: a systematic review and meta-analysis of randomised controlled trials","volume":"25","author":"Fujiwara Y","year":"2024","unstructured":"Fujiwara Y, Horita N, Adib E, et al.. Treatment-related adverse events, including fatal toxicities, in patients with solid tumours receiving neoadjuvant and adjuvant immune checkpoint blockade: a systematic review and meta-analysis of randomised controlled trials. Lancet Oncol. 2024, 25:62-75. 10.1016\/s1470-2045(23)00524-7","journal-title":"Lancet Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.08.007","article-title":"Pembrolizumab-induced encephalopathy: a review of neurological toxicities with immune checkpoint inhibitors","volume":"12","author":"Feng S","year":"2017","unstructured":"Feng S, Coward J, McCaffrey E, Coucher J, Kalokerinos P, O'Byrne K. Pembrolizumab-induced encephalopathy: a review of neurological toxicities with immune checkpoint inhibitors. J Thorac Oncol. 2017, 12:1626-35. 10.1016\/j.jtho.2017.08.007","journal-title":"J Thorac Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa H","year":"2019","unstructured":"Safa H, Johnson DH, Trinh VA, et al.. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer. 2019, 7:319. 10.1186\/s40425-019-0774-y","journal-title":"J Immunother Cancer"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0617-x","article-title":"Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study","volume":"7","author":"Johnson DB","year":"2019","unstructured":"Johnson DB, Manouchehri A, Haugh AM, et al.. Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J Immunother Cancer. 2019, 7:134. 10.1186\/s40425-019-0617-x","journal-title":"J Immunother Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.2643","article-title":"Triple M overlap syndrome (TMOS): evaluating immune checkpoint inhibitor-related overlap syndrome of myocarditis, myositis and myasthenia gravis using an international pharmacovigilance database","volume":"42","author":"Naqash AR","year":"2024","unstructured":"Naqash AR, Abushukair HM, Alghamdi E, et al.. Triple M overlap syndrome (TMOS): evaluating immune checkpoint inhibitor-related overlap syndrome of myocarditis, myositis and myasthenia gravis using an international pharmacovigilance database. J Clin Oncol. 2024, 42:2643. 10.1200\/JCO.2024.42.16_suppl.2643","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0359","article-title":"Diagnosis and management of immune checkpoint inhibitor-associated neurologic toxicity: illustrative case and review of the literature","volume":"24","author":"Reynolds KL","year":"2019","unstructured":"Reynolds KL, Guidon AC. Diagnosis and management of immune checkpoint inhibitor-associated neurologic toxicity: illustrative case and review of the literature. Oncologist. 2019, 24:435-43. 10.1634\/theoncologist.2018-0359","journal-title":"Oncologist"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0487","article-title":"Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis","volume":"22","author":"Larkin J","year":"2017","unstructured":"Larkin J, Chmielowski B, Lao CD, et al.. Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis. Oncologist. 2017, 22:709-18. 10.1634\/theoncologist.2016-0487","journal-title":"Oncologist"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25708","article-title":"Severe neurological toxicity of immune checkpoint inhibitors: growing spectrum","volume":"87","author":"Dubey D","year":"2020","unstructured":"Dubey D, David WS, Reynolds KL, et al.. Severe neurological toxicity of immune checkpoint inhibitors: growing spectrum. Ann Neurol. 2020, 87:659-69. 10.1002\/ana.25708","journal-title":"Ann Neurol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.3065","article-title":"Immune checkpoint inhibitor-induced cardiotoxicity: a systematic review and meta-analysis","volume":"10","author":"Nielsen DL","year":"2024","unstructured":"Nielsen DL, Juhl CB, Nielsen OH, Chen IM, Herrmann J. Immune checkpoint inhibitor-induced cardiotoxicity: a systematic review and meta-analysis. JAMA Oncol. 2024, 10:1390-9. 10.1001\/jamaoncol.2024.3065","journal-title":"JAMA Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab618","article-title":"Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis","volume":"42","author":"Dolladille C","year":"2021","unstructured":"Dolladille C, Akroun J, Morice PM, et al.. Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis. Eur Heart J. 2021, 42:4964-77. 10.1093\/eurheartj\/ehab618","journal-title":"Eur Heart J"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01808","article-title":"Incidence of cardiovascular events in patients treated with immune checkpoint inhibitors","volume":"40","author":"Laenens D","year":"2022","unstructured":"Laenens D, Yu Y, Santens B, et al.. Incidence of cardiovascular events in patients treated with immune checkpoint inhibitors. J Clin Oncol. 2022, 40:3430-8. 10.1200\/JCO.21.01808","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson DB","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML, et al.. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016, 375:1749-55. 10.1056\/NEJMoa1609214","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00369","article-title":"Major adverse cardiac events with immune checkpoint inhibitors: a pooled analysis of trials sponsored by the National Cancer Institute\u2014Cancer Therapy Evaluation Program","volume":"40","author":"Naqash AR","year":"2022","unstructured":"Naqash AR, Moey MY, Cherie Tan XW, et al.. Major adverse cardiac events with immune checkpoint inhibitors: a pooled analysis of trials sponsored by the National Cancer Institute\u2014Cancer Therapy Evaluation Program. J Clin Oncol. 2022, 40:3439-52. 10.1200\/JCO.22.00369","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-1180","article-title":"Abatacept\/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis","volume":"13","author":"Salem JE","year":"2023","unstructured":"Salem JE, Bretagne M, Abbar B, et al.. Abatacept\/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis. Cancer Discov. 2023, 13:1100-15. 10.1158\/2159-8290.CD-22-1180","journal-title":"Cancer Discov"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1901677","article-title":"Abatacept for severe immune checkpoint inhibitor-associated myocarditis","volume":"380","author":"Salem JE","year":"2019","unstructured":"Salem JE, Allenbach Y, Vozy A, Brechot N, Johnson DB, Moslehi JJ, Kerneis M. Abatacept for severe immune checkpoint inhibitor-associated myocarditis. N Engl J Med. 2019, 380:2377-9. 10.1056\/NEJMc1901677","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0299","article-title":"Immune-related adverse events by immune checkpoint inhibitors significantly predict durable efficacy even in responders with advanced non-small cell lung cancer","volume":"25","author":"Akamatsu H","year":"2020","unstructured":"Akamatsu H, Murakami E, Oyanagi J, et al.. Immune-related adverse events by immune checkpoint inhibitors significantly predict durable efficacy even in responders with advanced non-small cell lung cancer. Oncologist. 2020, 25:e679-83. 10.1634\/theoncologist.2019-0299","journal-title":"Oncologist"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17132063","article-title":"Management of triple M syndrome: a systematic review with narrative synthesis of immune checkpoint inhibitor-induced myasthenia gravis, myositis and myocarditis","volume":"17","author":"Furlepa M","year":"2025","unstructured":"Furlepa M, Watts I, Carr AS. Management of triple M syndrome: a systematic review with narrative synthesis of immune checkpoint inhibitor-induced myasthenia gravis, myositis and myocarditis. Cancers (Basel). 2025, 17:2063. 10.3390\/cancers17132063","journal-title":"Cancers (Basel)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.7567","article-title":"Multiorgan immune-related adverse events during treatment with atezolizumab","volume":"18","author":"Kichenadasse G","year":"2020","unstructured":"Kichenadasse G, Miners JO, Mangoni AA, Rowland A, Hopkins AM, Sorich MJ. Multiorgan immune-related adverse events during treatment with atezolizumab. J Natl Compr Canc Netw. 2020, 18:1191-9. 10.6004\/jnccn.2020.7567","journal-title":"J Natl Compr Canc Netw"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/ph16081119","article-title":"Opportunistic infections and immune-related adverse events associated with administering immune checkpoint inhibitors: a narrative review","volume":"16","author":"Oca\u00f1a-Guzm\u00e1n R","year":"2023","unstructured":"Oca\u00f1a-Guzm\u00e1n R, Osorio-P\u00e9rez D, Chavez-Galan L. Opportunistic infections and immune-related adverse events associated with administering immune checkpoint inhibitors: a narrative review. Pharmaceuticals (Basel). 2023, 16:1119. 10.3390\/ph16081119","journal-title":"Pharmaceuticals (Basel)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/492794-triple-m-overlap-syndrome-a-rare-complication-of-immune-checkpoint-inhibitors","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T16:50:09Z","timestamp":1788713409000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/492794-triple-m-overlap-syndrome-a-rare-complication-of-immune-checkpoint-inhibitors"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,6]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.115859","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,6]]}}}